Advertisement
Screener

Rapport Therapeutics, Inc. (RAPP) Graph

RAPP Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue $0.00; Research and development $51.41M; Selling, general and administrative $9.39M; Operating expenses $60.81M.
  • 2026-03-31: Revenue $20.00M; Research and development $32.72M; Selling, general and administrative $11.50M; Operating expenses $44.22M.
  • 2025-12-31: Revenue (m); Research and development $30.26M*; Selling, general and administrative (m); Operating expenses $38.51M*.
  • 2025-09-30: Revenue (m); Research and development $22.28M; Selling, general and administrative (m); Operating expenses $29.99M.

Revenue flow

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

RAPP revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Revenue$0.00Operating expenses$60.81MOperating income-$60.81MResearch & development$51.41MSelling, general& administrative$9.39MNet income-$56.62M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2026-06-30$0.00$51.41M$9.39M$60.81M(m)-$56.62M
2026-03-31$20.00M$32.72M$11.50M$44.22M(m)-$19.86M
2025-12-31(m)$30.26M*(m)$38.51M*(m)-$33.76M*
2025-09-30(m)$22.28M(m)$29.99M(m)-$26.93M
2025-06-30$0.00$22.68M$6.82M$29.50M(m)-$26.73M
2025-03-31$0.00$19.57M$7.54M$27.11M(m)-$24.06M
2024-09-30(m)$15.54M(m)$21.64M(m)-$17.54M
2024-06-30(m)$15.69M(m)$20.80M(m)-$18.12M
2024-03-31(m)$12.50M(m)$17.09M(m)-$22.67M
2023-09-30(m)$7.58M(m)$9.56M$1.00K-$8.71M
2023-06-30(m)$4.72M(m)$6.63M$2.00K-$6.41M
2023-03-31(m)(m)(m)(m)(m)-$6.15M

Revenue and expense 6 month

Period endRevenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2026-06-30$20.00M$84.13M$20.89M$105.02M(m)-$76.47M
2025-06-30$0.00$42.25M$14.35M$56.60M(m)-$50.80M
2024-06-30(m)$28.19M(m)$37.89M(m)-$40.79M
2023-06-30(m)$8.62M(m)$11.82M$3.00K-$12.56M

Revenue and expense 9 month

Period endResearch and developmentOperating expensesIncome taxNet income
2025-09-30$64.53M$86.59M(m)-$77.72M
2024-09-30$43.74M$59.53M(m)-$58.33M
2023-09-30$16.20M$21.39M$4.00K-$21.27M

Revenue and expense 12 month

Period endResearch and developmentOperating expensesIncome taxNet income
2025-12-31$94.79M$125.10M$0.00-$111.48M
2024-12-31$60.94M$83.06M$0.00-$78.31M
2023-12-31$28.00M$36.18M$10.00K-$34.79M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Stoke Therapeutics, Inc. (STOK)United States$1.630B-9.82
Xeris Biopharma Holdings, Inc. (XERS)United States$1.632B-80.10
Syndax Pharmaceuticals Inc (SNDX)United States$1.606B-8.82
Kailera Therapeutics, Inc. (KLRA)United States$1.552B
ANAPTYSBIO, INC (ANAB)United States$1.546B-60.20
Eton Pharmaceuticals, Inc. (ETON)United States$1.701B80.74
Innoviva, Inc. (INVA)United States$1.493B4.62
ArriVent BioPharma, Inc. (AVBP)United States$1.485B-10.25
Xencor Inc (XNCR)United States$1.776B-7.33
Septerna, Inc. (SEPN)United States$1.783B-63.01